NasdaqCM - Nasdaq Real Time Price ? USD Microbot Medical Inc. (MBOT) Follow Compare 0.9768 +0.0166 (+1.73%) At close: October 25 at 4:00 PM EDT 0.9770 +0.00 (+0.02%) After hours: October 25 at 6:44 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Microbot Medical Stock Rises After Completing ACCESS-PVI Trial MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission. Zacks ? 11 days ago MBOT +1.73% DGX ADUS Microbot eyes FDA application for surgical robot after completing pivotal trial The US robotics company is ramping up its go-to-market strategy ahead of potential US Food and Drug Administration (FDA) clearance in the second quarter of 2025 (Q2 2025). Medical Device Network ? 12 days ago MBOT +1.73% Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY? during 2Q 2025 U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY? Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial. The Company remains on track to file its 510(k) submission wi GlobeNewswire ? 12 days ago MBOT +1.73% Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule Microbot Medical Says it Expects to Finish its ACCESS-PVI Robotic Surgical System Clinical Trial Ahead of Schedule PREMIUM MT Newswires ? 27 days ago MBOT +1.73% Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY? Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY?. As a result of the inc GlobeNewswire ? 27 days ago MBOT +1.73% Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024BRAINTREE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY? Endovascular Robotic Surgical System, today announced that it has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling and completing the follow up of 50% of the patients participating in the trial to evaluate the LIBERTY GlobeNewswire ? last month MBOT +1.73% Microbot Medical advances Liberty Robotic System telesurgery innovation The system's capabilities are expected to address critical challenges in the healthcare sector. Medical Device Network ? last month MBOT +1.73% GLDAF Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY. Zacks ? 2 months ago MBOT +1.73% DGX Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY? Endovascular Robotic System The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within the Corewell Health system BRAINTREE, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY? Endovascular Robotic System, announces that it en GlobeNewswire ? 2 months ago MBOT +1.73% Microbot Medical (MBOT) Gets Quality Certification for its System Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization. Zacks ? 2 months ago MBOT +1.73% UHS DGX Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY? Endovascular Robotic Surgical System, today announces it has received ISO 13485:2016 certification for its quality management system. Receiving ISO 13485 certification indicates that a company has developed and implemented robust policies and procedures for the development and manufacture o GlobeNewswire ? 2 months ago MBOT +1.73% Microbot Medical (MBOT) Inks Deal to Test Autonomous Robotics Microbot Medical (MBOT) announces an agreement with Emory University to explore the potential of integrating robotics, procedure planning and navigation into a single autonomous system. Zacks ? 2 months ago MBOT +1.73% DGX ABM Microbot and Emory University to advance endovascular robotic system Emory will explore the feasibility of integrating the Microbot’s Liberty surgical system with an imaging system. Medical Device Network ? 2 months ago MBOT +1.73% Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY? Endovascular Robotic Surgical System The evaluation phase will explore the potential of integrating robotics, procedure planning and navigation into a single autonomous systemBRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory GlobeNewswire ? 2 months ago MBOT +1.73% Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of Miami as sites for the pivotal human clinical trialBRAINTREE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY? Endovascular Robotic Surgical System, today announces it has received Institutional Review Board (IRB) approval and signed a clinical trial agreement with Memorial Sloan Kettering Cancer Cen GlobeNewswire ? 3 months ago MBOT +1.73% Microbot Medical (MBOT) Progresses in Its Human Clinical Trial Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system. Zacks ? 3 months ago MBOT +1.73% SYK DVA Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical Trial. The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY? Endovascular Robotic Surgical System. BRAINTREE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that Baptist Hospital of Miami, which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute, GlobeNewswire ? 3 months ago MBOT +1.73% Microbot Medical Enrolled the First Patient in its?Pivotal Human Clinical Trial The first clinical case was performed at Brigham and Women’s Hospital The clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY? Endovascular Robotic Surgical System BRAINTREE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the completion of the first procedure in a patient utilizing its LIBERTY? Endovascular Robotic Surgical System. The procedure took place at Brigham and Women’s Hospital (B GlobeNewswire ? 3 months ago MBOT +1.73% Microbot Medical (MBOT) Inks Agreement to Begin LIBERTY Trial Microbot Medical's (MBOT) LIBERTY Endovascular Robotic System trial expands to Baptist Hospital of Miami, promising advancements in clinical outcomes and endovascular procedures. Zacks ? 3 months ago MBOT +1.73% UHS DVA Microbot secures second site for Liberty endovascular robot trial According to GlobalData, the surgical robotics market is set to reach $15.8bn by 2030, driven by the demand for less invasive options. Medical Device Network ? 3 months ago MBOT +1.73% Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return MBOT S&P 500 YTD -40.44% +21.77% 1-Year -22.48% +36.74% 3-Year -86.55% +27.79%
